Schedule of investments
Delaware Healthcare Fund | December 31, 2020 (Unaudited) |
Number of shares | Value (US $) | ||
Common Stock — 101.37%♦ | |||
Biotechnology — 33.15% | |||
ACADIA Pharmaceuticals † | 194,776 | $10,412,725 | |
Alder Biopharmaceuticals =, † | 75,000 | 66,000 | |
Alexion Pharmaceuticals † | 20,000 | 3,124,800 | |
Alkermes † | 423,142 | 8,441,683 | |
Allogene Therapeutics † | 146,779 | 3,704,702 | |
Alnylam Pharmaceuticals † | 41,000 | 5,328,770 | |
Amarin ADR † | 190,000 | 929,100 | |
AnaptysBio † | 93,732 | 2,015,238 | |
Arcus Biosciences † | 461,200 | 11,972,752 | |
Arena Pharmaceuticals † | 525,000 | 40,335,750 | |
Athenex † | 165,438 | 1,829,744 | |
BioMarin Pharmaceutical † | 129,000 | 11,312,010 | |
Cellectis ADR † | 226,875 | 6,139,238 | |
Clovis Oncology † | 250,200 | 1,200,960 | |
Coherus Biosciences † | 430,000 | 7,473,400 | |
Dynavax Technologies † | 760,000 | 3,382,000 | |
Epizyme † | 203,200 | 2,206,752 | |
Exact Sciences † | 96,353 | 12,765,809 | |
Five Prime Therapeutics † | 100,000 | 1,701,000 | |
Forma Therapeutics Holdings † | 92,786 | 3,238,231 | |
Fortress Biotech † | 100,000 | 317,000 | |
Galmed Pharmaceuticals † | 306,010 | 951,691 | |
Incyte † | 80,000 | 6,958,400 | |
Intellia Therapeutics † | 20,000 | 1,088,000 | |
Intercept Pharmaceuticals † | 27,000 | 666,900 | |
Karyopharm Therapeutics † | 380,000 | 5,882,400 | |
Lexicon Pharmaceuticals † | 11,697 | 40,004 | |
MacroGenics † | 420,000 | 9,601,200 | |
Madrigal Pharmaceuticals † | 28,500 | 3,168,345 | |
MEI Pharma † | 600,000 | 1,584,000 | |
Mersana Therapeutics † | 150,000 | 3,991,500 | |
Mirati Therapeutics † | 80,000 | 17,571,200 | |
MorphoSys † | 300,000 | 35,075,835 | |
Mustang Bio † | 120,000 | 454,200 | |
Myriad Genetics † | 135,000 | 2,669,625 | |
Nektar Therapeutics † | 256,385 | 4,358,545 | |
Neurocrine Biosciences † | 110,000 | 10,543,500 | |
NextCure † | 150,000 | 1,635,000 | |
Provention Bio † | 70,000 | 1,185,800 | |
Puma Biotechnology † | 61,255 | 628,476 | |
Regeneron Pharmaceuticals † | 90,000 | 43,479,900 | |
REGENXBIO † | 149,000 | 6,758,640 |
NQ-573 [12/20] 2/21 (1511506) 1
Schedule of investments
Delaware Healthcare Fund (Unaudited)
Number of shares | Value (US $) | ||
Common Stock♦ (continued) | |||
Biotechnology (continued) | |||
Rigel Pharmaceuticals † | 1,600,000 | $5,600,000 | |
Rocket Pharmaceuticals † | 58,000 | 3,180,720 | |
Sangamo Therapeutics † | 400,000 | 6,242,000 | |
Sarepta Therapeutics † | 23,000 | 3,921,270 | |
Seagen † | 95,000 | 16,638,300 | |
Sio Gene Therapies † | 64,171 | 178,395 | |
Surface Oncology † | 350,000 | 3,234,000 | |
Syndax Pharmaceuticals † | 180,000 | 4,003,200 | |
Translate Bio † | 456,300 | 8,409,609 | |
Ultragenyx Pharmaceutical † | 70,000 | 9,690,100 | |
uniQure † | 706,166 | 25,513,778 | |
United Therapeutics † | 86,800 | 13,175,372 | |
Vascular Biogenics † | 200,000 | 378,000 | |
Vertex Pharmaceuticals † | 25,000 | 5,908,500 | |
Viking Therapeutics † | 330,100 | 1,858,463 | |
Voyager Therapeutics † | 5,700 | 40,755 | |
Xencor † | 129,191 | 5,636,603 | |
XOMA † | 3,466 | 152,955 | |
Yumanity Therapeutics =, † | 750,000 | 0 | |
Yumanity Therapeutics † | 37,500 | 637,500 | |
410,590,345 | |||
Blue Chip Medical Products — 40.32% | |||
AbbVie | 226,559 | 24,275,797 | |
Amgen | 246,964 | 56,781,963 | |
AstraZeneca | 110,000 | 11,017,127 | |
AstraZeneca ADR | 82,000 | 4,099,180 | |
Biogen † | 45,000 | 11,018,700 | |
Boston Scientific † | 380,000 | 13,661,000 | |
Bristol-Myers Squibb | 200,000 | 12,406,000 | |
Chugai Pharmaceutical | 840,000 | 44,818,321 | |
Eli Lilly and Co. | 181,446 | 30,635,343 | |
Gilead Sciences | 310,000 | 18,060,600 | |
GlaxoSmithKline | 547,575 | 10,049,014 | |
GlaxoSmithKline ADR | 309,300 | 11,382,240 | |
Johnson & Johnson | 100,000 | 15,738,000 | |
Merck & Co. | 295,000 | 24,131,000 | |
Pfizer | 604,600 | 22,255,326 | |
Roche Holding | 180,000 | 62,693,742 | |
Sanofi | 380,000 | 36,534,665 | |
Sanofi ADR | 1,360,000 | 66,082,400 | |
Stryker | 15,000 | 3,675,600 |
2 NQ-573 [12/20] 2/21 (1511506)
(Unaudited)
Number of shares | Value (US $) | ||
Common Stock♦ (continued) | |||
Blue Chip Medical Products (continued) | |||
UCB | 76,000 | $7,843,579 | |
Zimmer Biomet Holdings | 80,000 | 12,327,200 | |
499,486,797 | |||
Healthcare Services — 8.60% | |||
Anthem | 87,500 | 28,095,375 | |
Change Healthcare † | 25,532 | 476,172 | |
Cigna | 75,000 | 15,613,500 | |
CVS Health | 180,000 | 12,294,000 | |
McKesson | 12,862 | 2,236,959 | |
Quest Diagnostics | 48,000 | 5,720,160 | |
UnitedHealth Group | 120,000 | 42,081,600 | |
106,517,766 | |||
Other — 11.31% | |||
China Mobile ADR | 240,000 | 6,849,600 | |
Cia de Minas Buenaventura ADR † | 66,353 | 808,843 | |
Compugen † | 690,000 | 8,355,900 | |
Fannie Mae † | 1,300,000 | 3,107,000 | |
Federal Home Loan Mortgage † | 1,050,000 | 2,446,500 | |
Micron Technology † | 1,172,000 | 88,110,960 | |
SINA † | 60,000 | 2,542,800 | |
SK Telecom ADR | 885,805 | 21,684,506 | |
Sohu.com ADR † | 390,722 | 6,228,109 | |
140,134,218 | |||
Small- / Mid-Cap Medical Products — 7.99% | |||
Aerie Pharmaceuticals † | 5,100 | 68,901 | |
Halozyme Therapeutics † | 230,000 | 9,823,300 | |
Illumina † | 102,000 | 37,740,000 | |
InnoCare Pharma 144A #, † | 17,000 | 29,560 | |
Inspire Medical Systems † | 30,000 | 5,642,700 | |
Intra-Cellular Therapies † | 450,000 | 14,310,000 | |
Perrigo | 210,000 | 9,391,200 | |
Viatris † | 1,170,018 | 21,926,137 | |
98,931,798 | |||
Total Common Stock (cost $917,819,914) | 1,255,660,924 | ||
Rights — 0.00% | |||
Ambit Bioscience =, † | 76,500 | 0 | |
Bristol-Myers Squibb † | 80,000 | 55,208 | |
Total Rights (cost $0) | 55,208 |
NQ-573 [12/20] 2/21 (1511506) 3
Schedule of investments
Delaware Healthcare Fund (Unaudited)
Number of shares | Value (US $) | ||
Rights (continued) | |||
Total Value of Securities—101.37% (cost $917,819,914) | 1,255,716,132 | ||
Liabilities Net of Receivables and Other Assets—(1.37%) | (16,991,015) | ||
Net Assets Applicable to 44,376,016 Shares Outstanding—100.00% | $1,238,725,117 |
♦ | Narrow industries are utilized for compliance purposes for diversification whereas broad sectors are used for financial reporting. |
† | Non-income producing security. |
= | The value of this security was determined using significant unobservable inputs and is reported as a Level 3 security. |
# | Security exempt from registration under Rule 144A of the Securities Act of 1933, as amended. At December 31, 2020, the aggregate value of Rule 144A securities was $29,560, which represents 0.00% of the Fund's net assets. |
Summary of abbreviations: |
ADR – American Depositary Receipt |
4 NQ-573 [12/20] 2/21 (1511506)